Navigation Links
GMSbiotech and Pure Transplant Solutions Announce Strategic Collaboration
Date:11/18/2013

Inverness, Ill and Oklahoma City, OK (PRWEB) November 18, 2013

GMSbiotech, Inc. (GMS), creator of novel microarray-based diagnostic solutions for personalized medicine and transplantation compatibility and Pure Transplant Solutions, LLC, (PTS) a leader in soluble HLA reagents production and application development, today announced a partnership that will leverage the GMS platform and the PTS soluble HLA technology including its suite of over 200 Class I and Class II alleles, anticipated to grow to 300 alleles over the duration of the project.

"We have invested over $15M in the last 14 years to develop the PTS reagent technology and GMS has invested over $10M in the last 10 years developing their platform," said Thomas Harlan, CEO Pure Transplant Solutions, "Leveraging our combined infrastructures and unique strengths will allow us to develop a novel technology solution while lowering the risk, time and costs normally associated with these types of ventures."

"We are excited about this collaboration and look forward to the development of a prototype which we hope to distribute by Q3 2014 to select ASHI certified labs for beta testing," said Dr. Krishna Jayaraman, President & CEO of GMSbiotech.

About GMSbiotech, Inc.

GMSbiotech (GMS) is a privately held company focusing on its patented microarray platform to develop accurate and affordable genetic and serology tests. With the company’s disruptive technology in Raw Sample Genotyping (RSG) combined with its microarray platform, complex genetic testing experienced by labs across the field has been substantially simplified into a routine, everyday low-cost component of clinical diagnostics and public health screening. The company is commercializing its technologies with an initial focus on transplantation diagnostics. For additional information on the company please visit http://www.gmsbiotech.com.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, L.L.C. ("PTS") is a subsidiary of Pure Protein L.L.C, a company that has developed and patented several soluble HLA protein technology methods and immunology tools for therapeutic and diagnostic applications in solid organ and stem cell transplantation, cross-reactive antibody screening, and major autoimmune diseases. Pure Protein was formed in 1999 to commercialize research developed by Dr. William Hildebrand at the University of Oklahoma Health Sciences Center. Pure Transplant Solutions was formed in 2003 to use HLA protein to develop diagnostics, devices, and therapeutics to help eliminate transplant rejection. To learn more visit http://www.pureproteinllc.com.

Pure Protein and its subsidiaries are funded and managed by innovation solutions company Emergent Technologies, Inc. For more information visit http://www.emergenttechnolgogies.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11341302.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Case Report Published in the Journal Perfusion on 14-Year-Old Pediatric Patient Bridged to Transplant with SynCardia Total Artificial Heart
2. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
3. UK’s 1st SynCardia Total Artificial Heart Patient Bridged to Transplant at Papworth Hospital
4. OrganJet customer receives kidney transplant years faster due to smart multiple listing
5. Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
6. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant
7. Universal Stem Cell Product Could Overcome Key Challenges in Donor Organ Transplants
8. SynCardia Total Artificial Heart Bridges Former Semi-Pro Arena Football Player to Heart Transplant
9. Researchers identify signals that direct the immune system to reject a transplanted organ
10. Stem cell transplant restores memory, learning in mice
11. Stem cells produce compact, regenerated bone in mandible transplants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, ... to help treat hormonal and stress related hair loss. With patent-pending formulas for ... of key opinion leaders in the medical and salon channels nationwide. , ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... talent development, skill-building and compliance training platform on mobile devices, today released a ... of Regulatory Requirements for Medical Devices. The course is essential for owners or ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/3/2016)... ... May 03, 2016 , ... Kerafast ... bioresearch materials from laboratories across the globe, today announced the availability of a ... pace of research toward treatment and prevention measures for the Zika virus, the ...
Breaking Biology Technology:
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 /PRNewswire/ ... offer Oncimmune,s Early CDT®-Lung, a blood test to ... lung cancer Early CDT®-Lung test to its ... --> Early CDT®-Lung test to its clients which ... Oncimmune, a leader in early cancer detection, today announced ...
(Date:3/2/2016)... , March 2, 2016 ... addition of the "Global Biometrics as ... their offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> Research and Markets ( ...
(Date:3/1/2016)... FRANCISCO , March 1, 2016  (RSAC Booth ... year, but a whopping $118 billion is lost to ... to overzealous and inaccurate fraud detection. At the RSA ... in the way companies handle authentication by devaluing the ... and behavioral analytics. --> ...
Breaking Biology News(10 mins):